EU and US could reach trade deal this weekend - Reuters
Investing.com -- Clearside Biomedical Inc . (NASDAQ:CLSD) stock surged 51% after Health Canada approved the company’s XIPERE treatment for uveitic macular edema, expanding the medication’s availability to a fourth global market.
The approval allows XIPERE (triamcinolone acetonide injectable suspension), which is administered using Clearside’s proprietary SCS Microinjector, to be marketed in Canada for treating macular edema associated with uveitis, a condition that can lead to vision loss. The treatment is already approved in the United States, Australia, and Singapore, with regulatory review ongoing in China.
Bausch + Lomb holds exclusive licensing rights for XIPERE’s commercialization and development in both the United States and Canada. Meanwhile, Arctic Vision, a China-based ophthalmic biotech company, has exclusive licensing rights for Greater China, South Korea, Australia, New Zealand, India, and ASEAN countries, where the product is marketed as ARCATUS or ARVN001.
Clearside’s SCS Microinjector technology enables targeted drug delivery to the back of the eye through an in-office procedure. The device consists of a syringe with a custom-designed hub and two 30-gauge hollow microneedles, each approximately one millimeter in length.
Beyond XIPERE, Clearside is advancing its pipeline with CLS-AX (axitinib injectable suspension), which is ready to enter Phase 3 trials for treating neovascular age-related macular degeneration.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.